scholarly journals mtDNA Haplogroup M5 Associated with Risk of Colorectal Cancer in South India Population

2021 ◽  
pp. 1863-1872
Author(s):  
B. Prathap Naidu ◽  
Pallaval Veera Bramhachari
Keyword(s):  
Colorectal Cancer ◽  
Mitochondrial Dna ◽  
Cancer Patients ◽  
Reference Sequence ◽  
Indian Populations ◽  
Indian Patients ◽  
South Indian ◽  
Increased Risk ◽  
Colorectal Cancer Patients ◽  
Mtdna Haplogroup

The life on earth is driven by energy, supplied by the tiny organelles of the cell called mitochondria and they are usually stated as the powerhouses of the cell.  In population genetics, Mitochondrial DNA (mtDNA) is used extensively to categorize individuals or populations.  The mutation sites observed in human mtDNA by comparing with the reference sequence (rCRS) are termed into definite human mtDNA haplogroups. Previous studies showed that mtDNA specific haplogroups and polymorphisms were established to be linked with various human diseases, including cancer in numerous populations. Furthermore, it is also known that several mitochondrial DNA polymorphisms are implicated in enhanced production of Reactive Oxygen Species (ROS) which are known to be an increased risk cause for several cancers, including colorectal cancer in Indian patients. Hence in our study, we made high resolution examination on mtDNA hypervariable region to trace the association of specific mtDNA haplogroup with colorectal cancer in south Indian populations. We report that mtDNA Haplogroup M was observed in 60% of the colorectal cancer patients and around 55% in the studied control samples. Haplogroup M is the most frequent mtDNA cluster found among south Indian populations. We further sub-lineated macro haplogroup M and found sub haplogroups (M8, M7, M6, M5, M3 and M2) in varied frequencies. In particular, we found significant association of haplogroup M5 with colorectal cancer patients (p = 0.026). Haplogroup M5 was observed in 12% of colorectal cancer patients in south Indian patients and in 3.3% of the control populations. These results suggest that individuals with haplogroup M5 may have significant risk to develop colorectal cancer.

scholarly journals Association between pre-diagnostic leukocyte mitochondrial DNA copy number and survival among colorectal cancer patients

2020 ◽  
Vol 68 ◽  
pp. 101778
Author(s):  
Keming Yang ◽  
Michele R. Forman ◽  
Brett H. Graham ◽  
Patrick O. Monahan ◽  
Edward L. Giovannucci ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mitochondrial Dna ◽  
Cancer Patients ◽  
Copy Number ◽  
Dna Copy Number ◽  
Mitochondrial Dna Copy Number ◽  
Colorectal Cancer Patients

Integrin genetic variants and risk of thromboembolic events in patients with colorectal cancer.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 462-462
Author(s):  
Gerald Prager ◽  
Alexandra Schuler ◽  
Cihan Ay ◽  
Clemens Pausz ◽  
Heinz-Josef Lenz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Tumor Biology ◽  
Multivariable Analysis ◽  
Significant Risk ◽  
Direct Dna Sequencing ◽  
Increased Risk ◽  
Colorectal Cancer Patients ◽  
Integrin Beta 3

462 Background: Patients with colorectal cancer are at increased risk of venous thromboembolism (VTE). Integrin beta-3 are involved in tumor biology as well as platelet aggregation, thus, we tested as a primary endpoint whether a comprehensive panel of germline single nucleotide polymorphisms (SNPs) in the integrin beta-3 gene could predict the risk of VTE in colorectal cancer patients. Methods: The study population comprises patients recruited into the Vienna Cancer and Thrombosis Study (CATS) (Ay, C et al; JCO 2011 vol. 29 no. 15), an ongoing prospective observational cohort study initiated in October 2003 at the Medical University of Vienna. In 114 out of 139 patients diagnosed with colon cancer DNA was assessable for integrin beta-3 germline SNPs rs3809865, rs5918, rs4642 characterization. Whole blood samples were analyzed using PCR-RFLP or direct DNA-sequencing. VTE events were statistical analyzed using one-way Anova testing. Results: The patient’s demographics and tumor characteristics were balanced between groups. VTE occurred in 14 patients (12.28%). In colorectal cancer patients with an rs3809865 A/A allele profile a statistical significant (p=0.0015) increased risk of VTE events was observed as 12 (25%) of 48 patients experienced VTE. Only 2 of 52 patients (3.85%) harboring an A/T allele VTE was diagnosed. None (0%) of the T/T subgroup had any VTE. Other SNPs revealed no predictive value for VTE. In multivariable analysis including age, sex, chemotherapy, and anti-VEGF therapy rs3809865 A/A allele profile remained a statistical significant risk factor for VTE. Conclusions: This study identifies germline polymorphisms in integrin genes as independent prognostic markers for VTE in colorectal cancer. These data may help to select subgroups of patients who may benefit from an enforced prophylaxis of venous thromboembolism (VTE).

Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

2009 ◽  
Vol 27 (15) ◽  
pp. 2457-2465 ◽  
Author(s):  
Erika Cecchin ◽  
Federico Innocenti ◽  
Mario D'Andrea ◽  
Giuseppe Corona ◽  
Elena De Mattia ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Objective Response ◽  
Area Under The Curve ◽  
Reference Sequence ◽  
Hematologic Toxicity ◽  
Pharmacokinetic Data ◽  
Severe Toxicity ◽  
Colorectal Cancer Patients

Purpose UGT1A1★28 is considered the main pharmacogenetic predictor of the toxicity outcome of irinotecan-treated patients. We evaluated the effect of other UGT1A variants and haplotypes involved in 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation on severe toxicity and efficacy of fluorouracil, leucovorin, and irinotecan (FOLFIRI). Patients and Methods In addition to UGT1A1★28, UGT1A1★60, UGT1A1★93, UGT1A7★3, and UGT1A9★22 were genotyped in 250 metastatic colorectal cancer patients, and associations with severe hematologic and nonhematologic toxicity, objective response, time to progression (TTP), and overall survival were evaluated. In a subset of 71 patients, pharmacokinetic data were also available. Results UGT1A7★3 was the only marker of severe hematologic toxicity after the first cycle (odds ratio [OR], 3.94; 95% CI, 1.05 to 14.82; P = .04) in a multivariate analysis. It was also associated with glucuronidation ratio (SN-38G area under the curve [AUC]/SN-38 AUC) and biliary index (irinotecan AUC) × (SN-38 AUC/SN-38G AUC). Haplotype I (all the reference sequence alleles but UGT1A9★22) was a predictor of severe hematologic toxicity during the entire course of therapy (OR, 0.39; 95% CI, 0.19 to 0.82; P = .01), together with sex (OR, 2.08; 95% CI, 1.01 to 4.28; P = .05). In addition to UGT1A1★28, haplotype II (all the variant alleles but UGT1A9★22) was associated with a response rate (OR, 8.61; 95% CI, 1.75 to 42.38; P = .01). UGT1A1★28 was the only marker associated with TTP. Conclusion We propose that UGT1A variants additional to UGT1A1★28 might improve the prediction of the outcome of colorectal cancer patients treated with FOLFIRI. A UGT1A haplotype-based approach might be an efficacious strategy to achieve treatment individualization of FOLFIRI.

scholarly journals 633Poorly controlled diabetes is a predictor of colorectal cancer survival

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Ming Li ◽  
David Roder
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Cancer Survival ◽  
Epidemiological Studies ◽  
Colorectal Cancer Survival ◽  
Increased Risk ◽  
History Of ◽  
Colorectal Cancer Patients ◽  
The Impact

Abstract Background Epidemiological studies have shown diabetes associated with increased risk of colorectal cancer. This study investigates the impact of a pre-cancer diabetes-related hospitalization record on colorectal cancer survival. Methods A retrospective cohort of 13190 colorectal cancer patients recorded on the South Australian Cancer Registry in 2003-2013 were examined. Diabetes-related hospitalization histories were obtained using linked inpatient data. Colorectal cancer deaths were available for 2003-2013. The association of survival from colorectal cancer with diabetes-related hospitalization history was assessed using competing risk analysis, adjusting for sociodemographic factors and cancer stage at diagnosis. Results 2765 patients with colorectal cancer (26.5%) had a history of hospital admission for diabetic complications, the most common being multiple complications (32%), followed by kidney and eye complications. The 5- and 10-year cancer survival probabilities were 63% and 56% in those with a diabetes complication history, significantly lower than 66% and 60% for patients without these complications (adjusted sub hazard ratio 1.11, 95% CI 1.02-1.20). Risk of colorectal cancer death was lower when theses diabetes-related hospitalizations were earlier than the year of cancer diagnosis - i.e., adjusted SHR 0.80, 95% CI 0.66-0.97 for 3-5 and 0.76, 95% CI 0.59-0.98 for 6+ years before the cancer diagnosis compared with same-year hospitalizations. Conclusions Colorectal cancer patients with a history of diabetes-related hospitalization have poorer survival, particularly if these hospitalizations were in the same year as the cancer diagnosis. Key messages Poorly controlled diabetes histories predict increased risk of colorectal cancer mortality.

39 Low-Density of CD3+ Cells At the Invasion Front and Increased Risk of Liver Metastases Development in Microsatellite-Stable Colorectal Cancer Patients

2008 ◽  
Vol 134 (4) ◽  
pp. A-5-A-6
Author(s):  
Elena Miranda ◽  
Emanuela Balladore ◽  
Paolo P. Bianchi ◽  
Alberto Mantovani ◽  
Alberto Malesci ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Cancer Patients ◽  
Low Density ◽  
Invasion Front ◽  
Increased Risk ◽  
Colorectal Cancer Patients

Baseline lymphopenia as a prognostic marker for colorectal carcinoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14107-e14107
Author(s):  
Dilek Erdem ◽  
Idris Yucel ◽  
Bahiddin Yilmaz ◽  
Guzin Demirag ◽  
Yasemin Kemal ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Lymphocyte Count ◽  
Statistical Significance ◽  
Disease Free Survival ◽  
Progression Free Survival ◽  
Hematological Toxicity ◽  
Free Survival ◽  
Increased Risk ◽  
Colorectal Cancer Patients

e14107 Background: Baseline lymphopenia has been proved to be a marker for poor prognosis, chemotherapy-induced toxicity and increased risk of febrile neutropenia, trombocytopenia and anemia in advanced solid neoplasms. This study aims to evaluate the effect of pretreatment lymphopenia on prognosis and hematological toxicity in colorectal cancer patients who received first line systemic chemotherapy. Methods: Lymphocyte count was evaluated in 386 pretreated colorectal cancer patients who do not have a seconder malignancy, HIV infection, bone involvement and primary G-CSF prophylaxis. Overall survival, progression free survival and disease free survival were calculated from date of diagnosis to date of relapse, progression and death. Kaplan-Meier, chi-square and Student-t test were used. Results: Mean follow-up was 30 months (range 1-180 months). Mean age was 57.4±12.5 years. Of all patients, 160 (41 %) were women. Rectum ( 26.2 %) and transvers colon (4.7 %) were the most and the least common anatomic locations, respectively. Mean lymphocyte count before treatment was 1964/µl (170-7000/µl). There were no relationship between lymphopenia and age, sex, performans status, presence of initial metastasis, adjuvant or palliative chemotherapy and hematological toxicity (p>0.05). Grade 3-4 hematological toxicity was found in 40 patients and was significantly higher in patients receiving bi- or tri-chemotherapy regimen (p:0.017). Among 208 patients with relapse or progression, 40 patients had lymphopenia (19.2 %). 1, 3 and 5-year OS were significantly lower in lymphopenic patients (p:0.033). DFS was longer in non-lymphopenic patients but this data didn’t have statistical significance (p>0.05). Conclusions: This study support that lymphocyte number prior to chemotherapy may be a simple but useful prognostic and predictive marker in untreated colorectal cancer patients. Patients with lower pretreatment lymphopenia have lower OS when compared to others (p<0.05). This study has the highest colorectal cancer population in the literature.

scholarly journals Genotyping of the Lactase-Phlorizin Hydrolase C/T-13910 Polymorphism by Means of a New Rapid Denaturing High-Performance Liquid Chromatography-Based Assay in Healthy Subjects and Colorectal Cancer Patients

2007 ◽  
Vol 12 (5) ◽  
pp. 733-739 ◽  
Author(s):  
Ada Piepoli ◽  
Enrico Schirru ◽  
Angela Mastrorilli ◽  
Annamaria Gentile ◽  
Rosa Cotugno ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Cancer Patients ◽  
Healthy Subjects ◽  
High Performance ◽  
Genetic Variant ◽  
Increased Risk ◽  
Colorectal Cancer Patients

Adult-type hypolactasia results from the progressive decline of lactase-phlorizin hydrolase activity in enterocytes after weaning. Lactase nonpersistence may determine a primary lactose intolerance with reduced diary product consumption, which is possibly related to an increased risk of colon cancer. Recently, a genetic variant C/T—13910 upstream of the lactase-phlorizin hydrolase ( LCT) gene has been strongly correlated with the lactase persistence/nonpersistence trait in both family and case-control studies. The authors validate a denaturing high-performance liquid chromatography (dHPLC)—based assay versus conventional genotype sequencing in detecting the C/T—13910 polymorphism of LCT and evaluate its prevalence in 2 different Italian geographical areas and in colorectal cancer patients. DNA samples of 157 healthy subjects and 124 colon cancer patients from Apulia and of 97 healthy subjects from Sardinia were evaluated for the C/T—13910 polymorphism by dHPLC, sequencing, and restriction fragment length polymorphism (RFLP). Under optimized conditions, dHPLC was as sensitive as DNA sequencing and detected a new genetic variant (T/C-13913) in 2 individuals that was not identified by RFLP assay. Frequency of lactase nonpersistence genotype (C/C—13910) was similar in healthy subjects from 2 different Italian geographical areas and not increased in patients with colorectal cancer. The results indicate that the dHPLC method may be used as a rapid, noninvasive, and laborsaving screening tool for genotyping C/T—13910 polymorphism, with high success, low cost, and reproducibility. ( Journal of Biomolecular Screening 2007:733-739)

scholarly journals DISTRIBUSI POLA DIET PASIEN KANKER KOLOREKTAL DI RSUD ULIN BANJARMASIN PERIODE AGUSTUS OKTOBER 2015

2016 ◽  
Vol 12 (2) ◽  
pp. 215
Author(s):  
Emma Rahmadania ◽  
Agung Ary Wibowo ◽  
Lena Rosida
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Age Group ◽  
Cross Sectional ◽  
Food Frequency ◽  
Consecutive Sampling ◽  
Keywords Colorectal Cancer ◽  
Increased Risk ◽  
Protein Fiber ◽  
Colorectal Cancer Patients

Abstract: Colorectal cancer is a malignancy of epithelial cells of the colon or rectum. Factors associated with an increased risk of this type of cancer include eating habits. The purpose of this study was to determine distribution the dietary patterns in colorectal cancer patients at hospitals Ulin Banjarmasin period from August to October 2015 by a review of fat dietary, protein dietary, fiber dietary  by age and gender. This research is a descriptive observasional with  cross sectional approach. Data was collected using a food frequency questionnaire and interviews. Sampling was conducted with consecutive sampling technique to obtain the sample amounted to 30 patients in accordance with the inclusion criteria. Obtained the age group of patients when first diagnosed with colorectal cancer is highest in the age group 41-60 years (50%) as many as 15 people. Sex ratio of colorectal cancer patients in hospitals Ulin Banjarmasin the period August-October 2015 that men of 15 people (50%) and women of 15 people (50%). Of the 30 respondents, there are 28 (93.4%) patients with colorectal cancer who rarely consume fat, there are 25 (83.4%) patients with colorectal cancer who rarely consume protein, and there were 25 (88.7%) patients with colorectal cancer are rare consuming fiber. Distribution of pattern dietary (fat, protein, fiber)by age and sex obtained the same result that most are in the rare category. Keywords: colorectal cancer, fat, protein, fiber. Abstrak: Kanker kolorektal adalah suatu keganasan dari sel epitel kolon atau rektum. Faktor yang berkaitan dengan peningkatan risiko kanker jenis ini antara lain kebiasaan makan. Tujuan penelitian ini adalah untuk mengetahui distribusi pola diet pasien kanker kolorektal  di RSUD Ulin Banjarmasin periode Agustus-Oktober  2015 dengan tinjauan terhadap diet lemak, diet protein, diet serat berdasarkan usia dan jenis kelamin. Penelitian ini merupakan penelitian yang bersifat deskriptif observasioal dengan pendekatan cross sectional. Data dikumpulkan dengan menggunakan lembar kuesioner food frequency dan wawancara. Pengambilan sampel  dilakukan dengan teknik consecutive sampling sehingga didapatkan sampel berjumlah 30 pasien yang sesuai dengan kriteria inklusi. Didapatkan kelompok usia pasien saat pertama kali terdiagnosis kanker kolorektal terbanyak adalah pada kelompok usia 41-60 tahun (50%) yaitu sebanyak 15 orang. Rasio perbandingan jenis kelamin pasien kanker kolorektal di RSUD Ulin Banjarmasin periode Agustus-Oktober 2015 yaitu laki-laki sebanyak  15 orang (50%)  dan perempuan sebanyak 15 orang (50%). Dari 30 responden, terdapat 28 (93,4%) pasien kanker kolorektal yang jarang mengkonsumsi lemak, terdapat 25 (83,4%) pasien kanker kolorektal yang jarang mengkonsumsi protein, dan terdapat 25 (88,7%) pasien kanker kolorektal yang jarang mengkonsumsi serat. Distribusi pola diet (lemak, protein, serat) berdasarkan usia dan jenis kelamin didapatkan hasil yang sama yaitu paling banyak berada pada kategori jarang. Kata-kata kunci: kanker kolorektal, lemak, protein, serat

scholarly journals Chemotherapy and adverse cardiovascular events in colorectal cancer patients undergoing surgical resection

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Chieh Yang Koo ◽  
Bee-Choo Tai ◽  
Dedrick Kok Hong Chan ◽  
Li Ling Tan ◽  
Ker Kan Tan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cardiovascular Disease ◽  
Cancer Patients ◽  
Surgical Resection ◽  
Lower Risk ◽  
Cardiovascular Death ◽  
Subdistribution Hazard ◽  
Chemotherapy Group ◽  
Increased Risk ◽  
Colorectal Cancer Patients

Abstract Background Colorectal cancer patients undergoing surgical resection are at increased short-term risk of post-operative adverse events. However, specific predictors for long-term major adverse cardiac and cerebrovascular events (MACCE) are unclear. We hypothesised that patients who receive chemotherapy are at higher risk of MACCE than those who did not. Methods In this retrospective study, 412 patients who underwent surgical resection for newly diagnosed colorectal cancer from January 2013 to April 2015 were grouped according to chemotherapy status. MACCE was defined as a composite of cardiovascular death, myocardial infarction, stroke, unplanned revascularisation, hospitalisation for heart failure or angina. Predictors of MACCE were identified using competing risks regression, with non-cardiovascular death a competing risk. Results There were 200 patients in the chemotherapy group and 212 patients in the non-chemotherapy group. The overall prevalence of prior cardiovascular disease was 20.9%. Over a median follow-up duration of 5.1 years from diagnosis, the incidence of MACCE was 13.3%. Diabetes mellitus and prior cardiovascular disease were associated with an increased risk of MACCE (subdistribution hazard ratio, 2.56; 95% CI, 1.48-4.42) and 2.38 (95% CI, 1.36-4.18) respectively. The chemotherapy group was associated with a lower risk of MACCE (subdistribution hazard ratio, 0.37; 95% CI, 0.19-0.75) compared to the non-chemotherapy group. Conclusions Amongst colorectal cancer patients undergoing surgical resection, there was a high incidence of MACCE. Diabetes mellitus and prior cardiovascular disease were associated with an increased risk of MACCE. Chemotherapy was associated with a lower risk of MACCE, but further research is required to clarify this association.

Sign in / Sign up

Export Citation Format

Share Document